Drugs / CBD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06648031 | Dec 2024 → Jul 2025 | type 2 diabetes mellitus | Lexaria Bioscience Corp. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06648031 ↗ |
| Route | Oral | “Route of administration: Oral” NCT06648031 ↗ |